Standardizing the dose and quality of platelet-rich plasma (PRP) is challenging due to variations in platelet concentration, machine processing, and individual disease processes.

“when you do a randomized control trial let's say for a medicine hypertensive medication you know what dose you're giving and you're comparing comp ing it to some other treatment where you know the dose platelet platelet rich plasma I'm taking your platelets of unknown concentration unknown quality of unknown quality I'm spinning it in a machine either once or twice and and a machine different machines concentrate those platelets differently and so then I end up with a product with a with a certain amount of platelets and then I inject it back into you I don't even know your disease process spe specifically”